Clinical trial
A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B
NCT02418793 is registered in ClinicalTrials.gov with OPKO Health, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B
- Lead sponsor
- OPKO Health, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 31, 2015
- Completion date
- September 30, 2018
- Enrollment
- 27 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.